A total of 211 pediatric patients aged 0–18 years who underwent tumor biomarker testing (CA-125, CA 19-9, CA 15-3, and CEA) at Adana City Training and Research Hospital between 1 November 2022 and 1 November 2023 were retrospectively included in this study. Here, CEACAM5 is linked to neoplasm.